Copeptin predicts clinical deterioration and persistent instability in community-acquired pneumonia

Kolditz, Martin; Halank, Michael; Schulte-Hubbert, B.; Bergmann, S.; Albrecht, Steffen; Höffken, G.

doi:10.1016/j.rmed.2012.06.008

Cited by 49 publications

(29 citation statements)

References 32 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mortality predictor in patients with a variety of underlying diseases presenting to the ED with acute dyspnea [20][21][22][23][24][25][26] and, especially, in patients with CAP [13,[27][28][29][30][31][32][33][34][35][36][37][38]; key studies are summarized in Table 1. Many of the dyspnea and CAP studies [20-23, 25-27, 29-31] had cohorts comprising > 25% of patients with COPD as a cormorbidity.…”

Section: Proadm In the Risk Assessment Of Patients With Other Pulmonamentioning

confidence: 99%

“…Vital status followup durations in these studies ranged from the hospital stay to 4 years. As with the COPD-focused studies, the CAP-and dyspnea-focused body of work has, albeit with limited exceptions [22,36], shown ProADM to be a strong, independent mortality predictor in multivariate analysis. Where combining ProADM with clinical/demographic/ other laboratory variables has been studied in dyspnea or CAP [23,24,32,35], the biomarker has provided significant incremental prognostic power.…”

Section: Proadm In the Risk Assessment Of Patients With Other Pulmonamentioning

confidence: 99%

“…There exists a substantial observational literature regarding ProADM use as an all-cause mortality predictor in patients with sepsis [11][12][13][14][15][16][17][18][19], in patients with a variety of underlying diseases presenting to the emergency department (ED) with acute dyspnea [20][21][22][23][24][25][26], and especially in patients with community-acquired pneumonia (CAP) [13,[27][28][29][30][31][32][33][34][35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review

Schuetz¹,

Marlowe²,

Müeller

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Plasma proadrenomedullin (ProADM) is a blood biomarker that may aid in multidimensional risk assessment of patients with chronic obstructive pulmonary disease (COPD). Co-secreted 1:1 with adrenomedullin (ADM), ProADM is a less biologically active, more chemically stable surrogate for this pluripotent regulatory peptide, which due to biological and ex vivo physical characteristics is difficult to reliably directly quantify. Upregulated by hypoxia, inflammatory cytokines, bacterial products, and shear stress and expressed widely in pulmonary cells and ubiquitously throughout the body, ADM exerts or mediates vasodilatory, natriuretic, diuretic, antioxidative, anti-inflammatory, antimicrobial, and metabolic effects. Observational data from four separate studies totaling 1366 patients suggest that as a single factor, ProADM is a significant independent, and accurate, long-term allcause mortality predictor in COPD. This body of work also suggests that combined with different groups of demographic/clinical variables, ProADM provides significant incremental long-term mortality prediction power relative to the groups of variables alone. Additionally, the literature contains indications that ProADM may be a global cardiopulmonary stress marker, potentially supplying prognostic information when cardiopulmonary exercise testing results such as 6-min walk distance are unavailable due to time or other resource constraints or to a patient's advanced disease. Prospective, randomized, controlled interventional studies are needed to demonstrate whether ProADM use in risk-based guidance of site-of-care, monitoring, and treatment decisions improves clinical, qualityof-life, or pharmacoeconomic outcomes in patients with COPD.

show abstract

Section: Proadm In the Risk Assessment Of Patients With Other Pulmonamentioning

confidence: 99%

Section: Proadm In the Risk Assessment Of Patients With Other Pulmonamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review

Schuetz¹,

Marlowe²,

Müeller

2015

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…High copeptin levels were also associated with clinical instability within 72 hours after admission. Copeptin performed similarly to the PSI and ATS/IDSA minor criteria and was better in predicting early instability and mortality than other biomarkers, including CRP, PCT, leukocyte count, and mid-regional proadrenomedullin (MR-proADM) [29]. In other studies, however, high MRproADM has been noted to carry a prognostic value not only in predicting mortality in patients with PSI class IV and V but also in predicting severity of illness and likelihood of complications, irrespective of the etiology [30][31][32].…”

Section: Biomarkers In Capmentioning

confidence: 94%

Management of community-acquired pneumonia

Ehsan¹,

Metersky

2013

Curr Respir Care Rep

View full text Add to dashboard Cite

This article summarizes recent literature related to community-acquired pneumonia (CAP), which continues to represent one of the most common causes of morbidity and mortality throughout the world, especially in the elderly. The impact is even more striking if we take healthcare costs into account. Patients with CAP usually have other comorbidities which not only increase mortality in this group but also add further to its economic burden. Patients with COPD, preexisting cardiac disease, and diabetes are particularly at higher risk for developing more severe pneumonia. New diagnostic modalities, including ultrasonography, are being used more commonly in clinical practice. Procalcitonin levels can be used to identify bacterial pneumonia and to de-escalate antibiotic therapy, resulting in fewer days on antibiotics. Other biomarkers have been used in studies to stratify patients by risk. Guideline-concordant regimens including atypical coverage, and macrolides in particular, appear to provide benefit. More recent data suggest the need for careful screening of patients for cardiovascular risk factors prior to initiating macrolides and fluoroquinolones.

show abstract

“…been shown to be a good predictor of short-and long-term all-cause mortality, superior to inflammatory markers, and at least comparable to "the confusion, respiratory rate, blood pressure, and age over 65 years (CRB-65)" score [8,9]. In severe chronic obstructive pulmonary disease, copeptin is an independent predictor of acute exacerbation together with chronic obstructive pulmonary disease assessment test (CAT).…”

mentioning

confidence: 99%